![](/img/cover-not-exists.png)
The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase
Masahide Yamamoto, Tetsuya Kurosu, Kazuhiko Kakihana, Daisuke Mizuchi, Osamu MiuraVolume:
319
Year:
2004
Language:
english
Pages:
1276
DOI:
10.1016/j.bbrc.2004.05.113
File:
PDF, 165 KB
english, 2004